Long-term evolocumab therapy leads to further reductions in cardiovascular events
Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients
29 August 2022Innovative randomized trial hints at mortality benefits with high-dose influenza vaccines
29 August 2022Long-term evolocumab therapy leads to further reductions in cardiovascular events
Long-term low-density lipoprotein (LDL) cholesterol lowering with evolocumab is safe and well tolerated and leads to further reductions in cardiovascular events compared with shorter treatment, according to late breaking results from the FOURIER open-label extension (OLE) study presented in a Hot Line session on 29 August at ESC Congress 2022.
